RU2012132429A - Бета-карболины для лечения нарушения слуха и головокружения - Google Patents

Бета-карболины для лечения нарушения слуха и головокружения Download PDF

Info

Publication number
RU2012132429A
RU2012132429A RU2012132429/04A RU2012132429A RU2012132429A RU 2012132429 A RU2012132429 A RU 2012132429A RU 2012132429/04 A RU2012132429/04 A RU 2012132429/04A RU 2012132429 A RU2012132429 A RU 2012132429A RU 2012132429 A RU2012132429 A RU 2012132429A
Authority
RU
Russia
Prior art keywords
carboline
cyclo
och
methyl
hearing impairment
Prior art date
Application number
RU2012132429/04A
Other languages
English (en)
Russian (ru)
Inventor
Ханс РОММЕЛЬШПАХЕР
Original Assignee
Аудиокьюр Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аудиокьюр Фарма Гмбх filed Critical Аудиокьюр Фарма Гмбх
Publication of RU2012132429A publication Critical patent/RU2012132429A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012132429/04A 2009-12-28 2010-12-28 Бета-карболины для лечения нарушения слуха и головокружения RU2012132429A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102009060811.7 2009-12-28
DE102009060811 2009-12-28
US28239510P 2010-02-02 2010-02-02
US61/282,395 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (1)

Publication Number Publication Date
RU2012132429A true RU2012132429A (ru) 2014-02-10

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012132429/04A RU2012132429A (ru) 2009-12-28 2010-12-28 Бета-карболины для лечения нарушения слуха и головокружения

Country Status (17)

Country Link
US (1) US9107914B2 (enExample)
EP (1) EP2519238B1 (enExample)
JP (1) JP5627705B2 (enExample)
KR (1) KR20120098855A (enExample)
CN (1) CN102844029A (enExample)
AU (1) AU2010338669A1 (enExample)
BR (1) BR112012015967B1 (enExample)
CA (1) CA2785233C (enExample)
DE (1) DE112010005017A5 (enExample)
IL (1) IL220661A (enExample)
IN (1) IN2012DN05066A (enExample)
MX (1) MX2012007678A (enExample)
NZ (1) NZ600478A (enExample)
RU (1) RU2012132429A (enExample)
SG (1) SG181599A1 (enExample)
WO (1) WO2011079841A1 (enExample)
ZA (1) ZA201204476B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
CN113416187B (zh) 2013-03-14 2024-07-19 奥斯菲治疗有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
EP2853533A1 (de) 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
ES3004565T3 (en) 2018-08-14 2025-03-12 Ossifi Therapeutics Llc Pyrrolo - dipyridine compounds for the treatment of bone loss
JP7695496B2 (ja) 2018-08-14 2025-06-19 オシフィ セラピューティクス リミティド ライアビリティ カンパニー フルオロβ-カルボリン化合物
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Jag−1を上方制御することにより有毛細胞を生成するための組成物及び方法
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
KR102899320B1 (ko) 2018-09-12 2025-12-12 호 이어 인스티튜트 인공 와우 수술에 따른 난청의 치료 방법
EP3772515A1 (en) * 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
ES2188184T3 (es) * 1998-06-12 2003-06-16 Sod Conseils Rech Applic Compuestos de beta-carbolinas.
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (de) 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen

Also Published As

Publication number Publication date
US9107914B2 (en) 2015-08-18
NZ600478A (en) 2013-10-25
MX2012007678A (es) 2012-09-12
CA2785233A1 (en) 2011-06-07
EP2519238A1 (de) 2012-11-07
JP5627705B2 (ja) 2014-11-19
EP2519238B1 (de) 2014-08-13
IN2012DN05066A (enExample) 2015-10-09
CN102844029A (zh) 2012-12-26
CA2785233C (en) 2018-10-09
BR112012015967A2 (pt) 2016-04-19
IL220661A0 (en) 2012-08-30
AU2010338669A1 (en) 2012-06-21
BR112012015967B1 (pt) 2019-08-27
US20130028958A1 (en) 2013-01-31
SG181599A1 (en) 2012-07-30
JP2013515752A (ja) 2013-05-09
DE112010005017A5 (de) 2012-10-04
WO2011079841A1 (de) 2011-07-07
KR20120098855A (ko) 2012-09-05
IL220661A (en) 2016-03-31
ZA201204476B (en) 2014-01-29

Similar Documents

Publication Publication Date Title
JP2013515752A5 (enExample)
RU2417993C9 (ru) Замещенные 2-хинолилоксазолы, пригодные в качестве ингибиторов фдэ4
RU2008129638A (ru) Производные пиразина в качестве блокатора эпителиального натриевого канала
RU2006125377A (ru) Гетероциклические ингибиторы аспартилпротеазы
RU2008130094A (ru) Модуляторы мускариновых рецепторов
JP2020502049A5 (enExample)
RU2014112692A (ru) Селективные и обратимые ингибиторы убихитин-специфической протеазы 7
RU2016144329A (ru) Агонисты рецептора апелина (apj) и его применение
RU2011147232A (ru) Производное карбоновой кислоты
RU2010126056A (ru) Органические соединения
RU2004125279A (ru) Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита c
PE20090733A1 (es) Derivados de pirazina como bloqueadores de los canales de sodio epitelial
RU2008150619A (ru) Производные пиразоло{3, 4-d}-пиримидина, применимые для лечения респираторных нарушений
RU2006134000A (ru) Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с
RU2001118466A (ru) Арил- и гетероциклилзамещенные пиримидиновые производные в качестве антикоагулянтов
JP2009502829A5 (enExample)
RU2014139169A (ru) Парентеральные составы для введения макролидных антибиотиков
CA2444103A1 (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
RU2008126245A (ru) Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции
JP2009502830A5 (enExample)
RU2002135312A (ru) Средство, усиливающие секрецию гормона роста
AR020321A1 (es) Derivados del acido antranilico, procedimiento para prepararlos, composiciones farmaceuticas formuladas con dichos derivados; uso de dichos derivados parala fabricacion de dichas composiciones y metodo para el tratamiento de enfermedades aplicando los derivados mencionados.
JP2023506787A (ja) Parp阻害薬と組み合わせたatr阻害薬の使用
RU2005137571A (ru) Новые производные диазабициклононена
JP2010505865A5 (enExample)

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20151228